CompletedNCT02977299
Switching or Adding Treatment for Depression That Has Not Responded to Antidepressants
About this title
Read the official source — NCT02977299Medication studyAges 18–80United States + Canada
Understand this study
Who was this study for?
Listed age limits: 18 years to 80 years.
- Listed locations
- Birmingham and 12 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: July 13, 2017
- Recruitment status
- Completed
- Enrollment listed in the registry
- 278
- Sponsor
- Massachusetts General Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Device, Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States, Canada
- Age range
- From 18 Years to 80 Years
- Official registry ID
- NCT02977299
- Official title
Show the full official title
Augmentation Versus Switch: Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With Treatment Resistant Depression (ASCERTAIN-TRD)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Birmingham, United States · Los Angeles, United States · Stanford, United States
10 more locations
- Tampa, United States
- Chicago, United States
- New York, United States
- Cincinnati, United States
- Philadelphia, United States
- Charleston, United States
- Dallas, United States
- Houston, United States
- Vancouver, Canada
- Winnipeg, Canada
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Massachusetts General Hospital, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Aripiprazole and Venlafaxine XR.
Who was this study for?
Listed age limits: 18 years to 80 years.
